Dendritic Vaccines

"Dendritic cell (DC)-based vaccines represent another strategy for cancer treatment. In a pilot study of patients with early-stage HER2-positive breast cancer, injection of a DC vaccine targeting HER2 was found to be safe and immunologically active, driving increased T-cell infiltration in tumors and potentially enhancing complete response rates when given before chemotherapy (1099)Soliman H, et al. (2025) NPJ Breast Cancer, 11: 29.. In another trial, a DC vaccine with personalized mutant KRAS peptides is being tested in patients with pancreatic cancer, demonstrating feasibility and laying the foundation for further study of DC vaccines in one of the deadliest cancer types (1100)Bear AS, et al. (2024) J Clin Invest, 134.."